
FDA Takes Steps to Modernize Drug Development
The agency is developing technology- and disease-specific regulatory frameworks for innovations that may not have previously had a clear development pathway.
FDA Commissioner Scott Gottlieb
The agency will be focusing on its approach to design of clinical trials and making the drug development process more efficient and less costly. A new pilot program has been designed to encourage the use of complex innovative trial designs. In addition, two new guidance documents have been published to provide clarity on next-generation therapies.
“The scientific opportunities we’re seeing today demand that we make sure our policies are as sophisticated as the treatments that are being developed. As the nature of drug discovery and development has become more focused on basic mechanisms of disease, targeted at specific genetic or molecular dysfunctions, science is bringing forward more novel opportunities to meaningfully address human disease,” Gottlieb stated in a press release.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.